Xylo Bio Advances Its Lead Into First-In-Human Clinical Trial

BOSTON – Xylo Bio confirmed that the first participants have been dosed in a Phase 1 clinical trial of XYL-1001, the company’s lead drug candidate targeting major depressive disorder (MDD). The trial is underway in Australia, and it marks the company’s transition from a preclinical to a clinical-stage running.

The study is structured as a randomized, double-blind, placebo-controlled investigation covering both single ascending dose and multiple ascending dose cohorts in healthy volunteers. Researchers will track XYL-1001’s safety profile, tolerability, pharmacokinetics, and pharmacodynamic activity. Several translational biomarkers are built into the trial to measure receptor engagement and inform future development decisions.

XYL-1001’s primary claim in an increasingly crowded neuropsychiatric field is specificity. The compound is engineered as a selective 5-HT2A receptor agonist designed to activate the serotonin pathway linked to antidepressant and neuroplastic effects, without triggering the hallucinatory responses that have made psychedelic-assisted therapy logistically demanding. To the company’s knowledge, it is the most selective 5-HT2A agonist in that category currently in human trials.

Chief Clinical Advisor Dr. Gabriel Vargas, MD, PhD, framed the stakes plainly: too many patients have exhausted existing options “without relief,” and the Phase 1 design is built to rigorously map XYL-1001’s pharmacology before any further advancement.

The market gap the company is chasing is documented. According to the World Health Organization, depressive disorders affect an estimated 332 million [!] people worldwide and are among the leading causes of disability globally. For roughly one in three patients, existing antidepressants fail to provide adequate relief after two or more treatment attempts – a persistent shortfall that has drawn a broad range of developers toward alternative mechanisms, including rapid-acting and receptor-targeted approaches.

Xylo Bio was founded in 2021 as Psylo and rebranded in 2025 to reflect its sharpened focus on neuroplastogens – molecules designed to rewire neural circuits and restore brain function without inducing the perceptual effects associated with classical psychedelics. The company maintains a strong presence on the University of New South Wales Kensington campus and has since expanded into the United States. Series Seed funding was secured with Tenmile in the lead and Main Sequence Ventures among the participants.

CSO and co-founder Dr. Samuel Banister, who is presenting the program this week at the 9th Neuropsychiatric Drug Development Summit in Boston, puts the company’s aim in direct terms: to “unlock the therapeutic potential of the 5-HT2A receptor” without the hallucinogenic burden that limits treatment access.

That framing draws a line in the field. Most companies working in the psychedelic-adjacent space have spent years building infrastructure around supervised clinical protocols, therapist training, and controlled dosing environments. Xylo is working from a different premise entirely; that clinically meaningful antidepressant effects are achievable through targeted receptor engagement alone. Safety and pharmacokinetic data from the Australian trial, expected in late 2026 or early 2027, will offer the first real-world test of that thesis. For investors and operators watching the neuropsychiatric drug space, those readouts will carry weight well beyond one company’s pipeline.

Image courtesy: xylo.bio